相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Biologic markers determine both the risk and the timing of recurrence in breast cancer
Laura J. Esserman et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
E. Razis et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer
Jeanette Dupont Jensen et al.
CLINICAL CANCER RESEARCH (2011)
Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers
Bhuvanesh Dave et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
Luca Gianni et al.
LANCET ONCOLOGY (2011)
PTEN, PIK3CA, p-AKT, and p-p70S6K Status Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer
Francisco J. Esteva et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
Y. Kataoka et al.
ANNALS OF ONCOLOGY (2010)
Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer
R. B. Costa et al.
ANNALS OF ONCOLOGY (2010)
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
Matthew J. Ellis et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations Diagnostic and Clinical Implications
Athanasios C. Tsiatis et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2010)
Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
Neil A. O'Brien et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Molecular predictors of response to trastuzumab and lapatinib in breast cancer
Francisco J. Esteva et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Protocol for PTEN Expression by Immunohistochemistry in Formalin-fixed Paraffin-embedded Human Breast Carcinoma
Rita A. Sakr et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2010)
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
Isabel F. Pinhel et al.
BREAST CANCER RESEARCH (2010)
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
S. Gori et al.
ANNALS OF ONCOLOGY (2009)
Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab
Dana Faratian et al.
CANCER RESEARCH (2009)
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kevin Kalinsky et al.
CLINICAL CANCER RESEARCH (2009)
Resistance to Trastuzumab in Breast Cancer
Paula R. Pohlmann et al.
CLINICAL CANCER RESEARCH (2009)
Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors
Thomas Frogne et al.
BREAST CANCER RESEARCH (2009)
Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic variables
Birgitte Bruun Rasmussen et al.
ACTA ONCOLOGICA (2008)
PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients
Yuen-Liang Lai et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
Pieter J. A. Eichhorn et al.
CANCER RESEARCH (2008)
Circumventing de novo and acquired resistance to trastuzumab: New hope for the care of ErbB2-positive breast cancer
Martine Piccart
CLINICAL BREAST CANCER (2008)
The role of PTEN signaling perturbations in cancer and in targeted therapy
M. Keniry et al.
ONCOGENE (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines
C. Ginestier et al.
ONCOGENE (2007)
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas
Mattia Barbareschi et al.
CLINICAL CANCER RESEARCH (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer
Gizeh Perez-Tenorio et al.
CLINICAL CANCER RESEARCH (2007)
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
Clifford A. Hudis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy
Filippo Montemurro et al.
ONCOLOGIST (2006)
PIK3CA mutations in breast cancer are associated with poor outcome
SY Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer
G Hudelist et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients
J Cicenas et al.
EUROPEAN JOURNAL OF CANCER (2006)
PIK3CA mutation and histological type in breast carcinoma:: high frequency of mutations in lobular carcinoma
F Buttitta et al.
JOURNAL OF PATHOLOGY (2006)
Cancer-specific mutations in PIK3CA are oncogenic in vivo
AG Bader et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
T Fujita et al.
BRITISH JOURNAL OF CANCER (2006)
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells
SJ Isakoff et al.
CANCER RESEARCH (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Stability of phosphoprotein as a biological marker of tumor signaling
AF Baker et al.
CLINICAL CANCER RESEARCH (2005)
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
LH Saal et al.
CANCER RESEARCH (2005)
Phosphotyrosine interactome of the ErbB-receptor kinase family
Waltraud X. Schulze et al.
MOLECULAR SYSTEMS BIOLOGY (2005)
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
SY Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
GJ Wu et al.
BREAST CANCER RESEARCH (2005)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
The PIK3CA gene is mutated with high frequency in human breast cancers
KE Bachman et al.
CANCER BIOLOGY & THERAPY (2004)
Mutation of the PIK3CA gene in ovarian and breast cancer
IG Campbell et al.
CANCER RESEARCH (2004)
Her-2/neu-triggered intracellular tyrosine kinase activation:: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment
G Hudelist et al.
BRITISH JOURNAL OF CANCER (2003)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
